Telomir Pharmaceuticals, Inc.
TELO
$4.53
-$0.505-10.04%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 10.01M | 8.25M | 3.56M | 3.44M | 2.37M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 12.30M | 10.48M | 5.42M | 5.38M | 3.94M |
| Operating Income | -12.30M | -10.48M | -5.42M | -5.38M | -3.94M |
| Income Before Tax | -16.59M | -23.02M | -18.74M | -18.84M | -13.07M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -16.59 | -23.02 | -18.74 | -18.84 | -13.07 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -16.59M | -23.02M | -18.74M | -18.84M | -13.07M |
| EBIT | -12.30M | -10.48M | -5.42M | -5.38M | -3.94M |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -0.57 | -0.82 | -0.68 | -0.69 | -0.48 |
| Normalized Basic EPS | -0.36 | -0.34 | -0.25 | -0.26 | -0.13 |
| EPS Diluted | -0.57 | -0.82 | -0.68 | -0.69 | -0.48 |
| Normalized Diluted EPS | -0.36 | -0.34 | -0.25 | -0.26 | -0.13 |
| Average Basic Shares Outstanding | 116.65M | 114.09M | 111.57M | 109.06M | 108.19M |
| Average Diluted Shares Outstanding | 116.65M | 114.09M | 111.57M | 109.06M | 108.19M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
